Company profilePharmaceutical#67 of 1,318 in Pakistan6 DRAP alerts

SAFE PHARMACEUTICAL (PVT) LTD.

Pharmaceutical company · 212 brands · 200 molecules

Ranked #51 of 78 companies in Antiepileptics

212 registered products 67 pharmaceutical brands 200 distinct molecules 6 DRAP alerts

Company overview

212
registered products
67
pharmaceutical brands
200
distinct molecules
4
therapeutic classes
6
DRAP alerts

SAFE PHARMACEUTICAL (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 212 product registrations across 200 distinct molecules. It is the 67th largest registrant in Pakistan by product count, and ranks 51st of 78 in Antiepileptics. Its portfolio is concentrated in Antiepileptics and Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). DRAP has issued 6 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by SAFE

138 products matched in our catalogue · showing 80 — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

136
ceilings with an approval date
128
not revised in 2+ years
2024
oldest approval year
2024128
20256
20262
Longest without revision

Top molecules by brand count

Linezolid7 brands
Amikacin6 brands
Tacrolimus6 brands
Cephalexin6 brands
Artemether5 brands
Paracetamol5 brands

Therapeutic classes

Antiepileptics · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Vitamin B12 Plain · 1Blood Glucose Lowering Drugs, Excluding Insulin · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official234 products · Rs 13.51 – Rs 7,831.12
Median across source: Rs 292.69

Regulatory record

6 alerts in the DRAP feed we track.

Strategic Plan 2026-2030
2026-05-06
Directive on the security of online portals and engagement with authorized personnel/consu
2026-04-30
Drug Safety Alert: Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversi
2024-05-07
DRAP invites Comments on Draft Guideline for Storage and Destruction of Substandard-Falsif
2023-10-27
The National Pharmacovigilance Center, DRAP urge the manufacturers and importers to nomina
2023-08-23
Drug Product Recall; Water for Injection (Batch#LI-961) by M/s Safe Pharmaceuticals Pvt. L
2022-03-29

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

MEDIATE PHARMACEUTICALS (PVT) LTD holds 78 molecules not in this portfolio
AlendronateAmlodipineAmoxicillinAmpicillinAmpicillin BaseAnastrozole
BIO LABS (PVT) LTD. holds 109 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherAscorbic AcidAtorvastatin
MACTER INTERNATIONAL (PVT) LTD. holds 149 molecules not in this portfolio
000 I.U10Ug Polysaccharides Covalently Bound To 20Ug To 32Ug Of Tetanus ToxoidAlbendazoleAlbuterolAlfacalcidolAluminium Hydroxide

Get the full profile for SAFE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.